Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNALGOS-DC vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydrocodeine is a semisynthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby providing analgesic and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia by reducing pain perception and increasing the efficacy of other analgesics.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Moderate to moderately severe pain,Relief of pain accompanied by inflammation or fever (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
1-2 capsules orally every 4 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg. Maximum: 8 capsules per day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Dihydrocodeine: 3.5-4.5 hours; aspirin: 15-20 minutes; caffeine: 3-6 hours. Context: Dihydrocodeine half-life supports q4-6h dosing; aspirin short half-life limits analgesia duration.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Dihydrocodeine is metabolized primarily via O-demethylation and N-demethylation in the liver, mediated by CYP2D6 and CYP3A4, to active metabolites including dihydromorphine. Aspirin is hydrolyzed to salicylic acid, which undergoes conjugation with glycine and glucuronic acid, and oxidative metabolism. Caffeine is metabolized by CYP1A2 to paraxanthine, theobromine, and theophylline.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: ~90% (dihydrocodeine, as metabolites, primarily glucuronides); biliary/fecal: ~10%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Dihydrocodeine: ~20-30% (albumin); aspirin: ~50-80% (albumin, saturable); caffeine: ~25-36% (albumin).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Dihydrocodeine: 1.2-1.7 L/kg; clinical meaning: distributes extensively into tissues, including CNS.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: Dihydrocodeine ~70-80% (first-pass metabolism); aspirin: 40-50% (due to hydrolysis in gut wall/liver); caffeine: nearly 100%.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Avoid use if Cr Cl < 30 m L/min due to accumulation of dihydrocodeine and acetaminophen. For Cr Cl 30-60 m L/min, extend dosing interval to every 6 hours and monitor closely. For Cr Cl > 60 m L/min, no adjustment needed.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% and monitor for hepatotoxicity. In mild impairment (Child-Pugh A), no adjustment but caution.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not recommended for pediatric patients due to variable metabolism of dihydrocodeine and risk of respiratory depression. Specific weight-based dosing not established; alternative agents preferred.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lowest effective dose (1 capsule every 6 hours). Monitor for CNS depression, falls, and constipation. Avoid in frail elderly due to increased sensitivity and risk of toxicity from acetaminophen accumulation.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE OF BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS FROM CONCOMITANT USE WITH ALCOHOL. See full prescribing information.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,CYP3A4 interaction (potent inhibitors or inducers),Concomitant use with benzodiazepines or other CNS depressants,Risk of bleeding (aspirin),Reye's syndrome (aspirin use in viral infections in children),Serotonin syndrome (with serotonergic drugs),Adrenal insufficiency,Hypotension, including orthostatic hypotension,Seizures,Increased intracranial pressure,Gastrointestinal adverse effects (aspirin),Renal impairment,Hepatic impairment
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to dihydrocodeine, aspirin, caffeine, or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Severe bleeding disorders (aspirin),Children and teenagers with viral infections (risk of Reye's syndrome),Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy,Severe hepatic impairment,Severe renal impairment
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol and grapefruit juice. High-fat meals may delay the absorption of dihydrocodeine, potentially reducing the peak effect. Maintain adequate hydration to prevent constipation. No other specific dietary restrictions.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Association with neural tube defects and congenital heart defects with opioid use. Second/third trimesters: Risk of miscarriage, preterm birth, fetal growth restriction, and neonatal abstinence syndrome with chronic use. No specific data on dihydrocodeine combination; teratogenic risk considered low from oral contraceptives, but paracetamol/aspirin/caffeine components may contribute.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Dihydrocodeine and paracetamol are excreted into breast milk. Milk-to-plasma ratio (M/P) for dihydrocodeine is approximately 2.4; for paracetamol, M/P ~1.0 (but clinically negligible). Aspirin (as present in some formulations) is excreted with M/P 0.01–0.1; risk of Reye syndrome in infants. Caffeine M/P ~0.5–0.8. Use caution; benefit-risk evaluation required.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy generally increases clearance of paracetamol and dihydrocodeine; however, no specific dose adjustment recommendations. Use lowest effective dose for shortest duration. Consider avoiding aspirin component in third trimester due to premature ductus arteriosus closure risk. Caffeine dose not adjusted but limit intake.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
SYNALGOS-DC contains dihydrocodeine, a prodrug metabolized to dihydromorphine via CYP2D6. Co-administration with CYP2D6 inhibitors (e.g., paroxetine) or inducers may alter analgesia. Avoid in patients with severe respiratory depression, paralytic ileus, or history of opioid addiction. Monitor for serotonin syndrome if combined with serotonergic agents. Use with caution in elderly or debilitated patients due to increased fall risk.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Do not exceed the prescribed dose; risk of addiction and overdose increases with higher doses.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they may cause dangerous sedation or respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take with food if nausea occurs; avoid high-fat meals as they may delay absorption.,Store in a secure place; dispose of unused medication via take-back programs to prevent misuse.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNALGOS-DC vs ABSTRAL, answered by our medical review team.
SYNALGOS-DC is a Opioid Analgesic that works by Dihydrocodeine is a semisynthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby providing analgesic and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia by reducing pain perception and increasing the efficacy of other analgesics.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNALGOS-DC and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNALGOS-DC is: 1-2 capsules orally every 4 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg. Maximum: 8 capsules per day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNALGOS-DC and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNALGOS-DC is classified as Category C. First trimester: Association with neural tube defects and congenital heart defects with opioid use. Second/third trimesters: Risk of miscarriage, preterm birth, fetal growth restri. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.